trending Market Intelligence /marketintelligence/en/news-insights/trending/VrE-phN_eO1ZVfNpAZJqhw2 content esgSubNav
In This List

Japan approves Novocure's brain tumor treatment

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Japan approves Novocure's brain tumor treatment

Japan's Ministry of Health, Labour and Welfare approved NovoCure Ltd.'s Optune treatment for patients with a newly diagnosed brain tumor.

The treatment is already approved for patients suffering from recurrent supra-tentorial glioblastoma, the most common primary brain tumor among adults.

Approximately 1,500 patients are diagnosed with glioblastoma in Japan each year.